Efficacy of Cashew Nut Protein Immunotherapy

Status Not yet recruiting

Clinical Trial Summary

It is a randomized, sigle-center, controlled trial to evaluate the effectiveness of oral immunotherapy with cashew protein compared with standard treatment (elimination diet) in pediatric patients with cashew allergy.

Clinical Trial Description

According to Polish data, in the population of children suspected of food allergy, cashew was the third nut found to be allergic, after peanut and hazelnut. Allergic reactions to nuts can be severe and life-threatening, making it challenging to avoid hidden sources of the allergen. An effective and safe alternative to allergen avoidance strategies may be the use of oral specific immunotherapy. In this study 39 children, aged 4 to 17 years with a diagnosis of IgE-dependent allergy to cashew, confirmed by an open oral provocation test (OFC; the first provocation before starting oral desensitization), will be randomly (2:1) assigned to two groups. The first group will be desensitized with a maintenance dose - 1200mg of cashew protein, while the second group - the control group - will be offered standard management - avoidance of cashew consumption. Patients in the control group will be offered immunotherapy at the end of the study if its effectiveness is confirmed. The desensitization procedure was planned in accordance with the guidelines for immunotherapy in food allergy of the European Academy of Allergology and Clinical Immunology. The source of cashew protein is flour. The first dose of immunotherapy is given to patients in the intervention group in the hospital ward. The size of the initial dose depends on the symptom-triggering dose during the initial oral food provocation with cashew protein. Every 2 weeks in the hospital setting, another higher dose of cashew protein will be given to the child. The requirement for increasing the dose of cashew is to achieve full tolerance of the previous dose. The maximum duration of this phase is 60 weeks. After the maximum dose is tolerated, desensitization will continue for 12 weeks - the maintenance phase of desensitization. The maintenance dose is 1200mg of cashew protein. The duration of the maintenance phase is 12 weeks (+/-3 weeks). After 12 weeks +/-3 weeks of maintenance dose, OFC and cashew protein tolerance assessment will be performed. Confirmation of complete cashew tolerance is the tolerance of a dose of 4043mg of cashew protein. Primary outcomes include the proportion of participants tolerating a single dose of 4043mg cashew protein during the final oral food challenge. Secondary outcomes assess adverse events, changes in immunological parameters, and the maximum tolerated doses of cashew protein in each group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06328504
Study type	Interventional
Source	Medical University of Warsaw
Contact	Katarzyna Grzela, PhD, MD
Phone	+48223179431
Email	katarzyna.grzela@wum.edu.pl
Status	Not yet recruiting
Phase	N/A
Start date	March 2024
Completion date	April 21, 2027

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03089476` - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy	N/A
Recruiting	`NCT05839405` - Food Allergy in the Brain
Completed	`NCT02552537` - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions	Phase 4
Completed	`NCT01634737` - Crustacean Allergy and Dust Mites Sensitization	N/A
Completed	`NCT05072665` - Fast Allergy Sensitivity Test	N/A
Active, not recruiting	`NCT04887441` - Allergology: Information, Data and Knowledge Organization
Recruiting	`NCT03265262` - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy	N/A
Completed	`NCT04186949` - Early Origins of Allergy and Asthma
Completed	`NCT02490007` - Pertussis Immunisation and Food Allergy
Recruiting	`NCT03151252` - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract	N/A
Completed	`NCT02159833` - Intranasal Diagnostics in Food Allergy: a Feasibility Study	N/A
Completed	`NCT02377284` - Prevention and Management of Food Allergies	N/A
Completed	`NCT02354729` - Encouraging Allergic Young Adults to Carry Epinephrine	N/A
Completed	`NCT02640560` - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish	N/A
Enrolling by invitation	`NCT06097572` - Improved Diagnostics in Food Allergy Study	N/A
Recruiting	`NCT04606615` - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting	`NCT05785299` - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy	N/A
Not yet recruiting	`NCT06112873` - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed	`NCT03337802` - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring	N/A
Not yet recruiting	`NCT06085118` - Observatory on Cow's Milk Protein Allergy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.